Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zostavax User Fee Date Extended To May

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is extending the user fee date for Merck's zoster vaccine Zostavax by three months to May 25 in order to review additional information provided by the firm, Merck said Feb. 24

You may also be interested in...



Merck Gardasil Slated For Advisory Committee Review May 18

Vaccines & Related Biological Products committee will review HPV vaccine less than a month ahead of June 8 priority review user fee date.

Merck Gardasil Slated For Advisory Committee Review May 18

Vaccines & Related Biological Products committee will review HPV vaccine less than a month ahead of June 8 priority review user fee date.

Merck Zostavax Shingles Vaccine Safe and Effective For Adults Over 60, Committee Says

FDA's Vaccines & Related Biological Products Advisory Committee said data do not support Merck's proposed indication for adults as young as 50 years.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel